

## PRESCRIBING ANTICOAGULANTS

**Recommended prescribing options within Hull and East Riding, for patients requiring anticoagulation:** (Please note NICE CG180 recommends that prescribers discuss the options for anticoagulation with the person and base the choice on their clinical features and preferences)

Atrial Fibrillation ( <a href="#">see SPAF guideline</a> )			
		Recommended options	
Non-valvular AF (NVAF) SPAF Primary prevention	warfarin or edoxaban apixaban, dabigatran or rivaroxaban		
Non-valvular AF (NVAF) SPAF secondary prevention	warfarin or apixaban or rivaroxaban dabigatran or edoxaban		
	Recommended option	Also approved	
Valvular AF	warfarin	Consider patient specific need	
Heart Valve			
Prosthetic valve replacement	warfarin	Consider patient specific need DOACs* are contraindicated	
VTE Treatment			
DVT & PE  Duration as per indication	1 <sup>st</sup> choice Apixaban	2 <sup>nd</sup> choice LMWH plus warfarin**	rivaroxaban or long term LMWH or LMWH plus dabigatran*** or LMWH plus edoxaban***
Secondary Prevention of artherothrombotic events			
Coronary or peripheral artery disease Duration as per specialist	Rivaroxaban plus aspirin OR warfarin		
Acute coronary syndrome Review after 12 months	Rivaroxaban with aspirin 75mg OD and clopidogrel or with aspirin alone		
Orthopaedics ( <i>2<sup>nd</sup> care only for full supply</i> )			
VTE Prophylaxis after orthopaedic surgery	1 <sup>st</sup> choice dabigatran	2 <sup>nd</sup> choice LMWH	apixaban or rivaroxaban
VTE Prophylaxis after Lower Limb Injury	1 <sup>st</sup> choice dabigatran	2 <sup>nd</sup> choice LMWH	apixaban or rivaroxaban
Specialist groups			
Treatment & prophylaxis in patients with active cancer	rivaroxaban or apixaban( <a href="#">see guideline</a> ) or LMWH		Consider patient specific need.
Treatment & prophylaxis in pregnancy	LMWH		Consider patient specific need
Medical / Surgical prophylaxis	LMWH		fondaparinux
Administration of meds	DOACs* preferred option for patients using compliance aids. Dabigatran is not stable in multi-compartment compliance aids. Apixaban, edoxaban and rivaroxaban can be used for enteral tube administration		

LMWH of choice: Dalteparin (this might change at times of supply disruption)

\*DOACs = Direct oral anticoagulants = apixaban, dabigatran, edoxaban, rivaroxaban

\*\* for DVT/PE treatment with warfarin continue LMWH until INR in range for 2 days, minimum 5 days LMWH

\*\*\*for DVT/PE treatment with dabigatran or edoxaban at least 5 days treatment with LMWH required before change to dabigatran

- For further prescribing information see clinical information below

- For information on changing anticoagulants in an individual patient – refer to data sheet [www.medicines.org.uk](http://www.medicines.org.uk)

## RECOMMENDED DOSES BY INDICATION FOR DIRECT ORAL ANTICOAGULANTS

Renal function should be monitored regularly (every 6 to 12 months, increase frequency if renal function deteriorating). See page 4 for further advice

DRUG	Stroke Prevention in Atrial Fibrillation	DVT / PE Treatment prophylaxis	Treatment Prophylaxis Orthopaedics 2 <sup>nd</sup> Care Supply
<b>Apixaban</b>	<b>Standard dose 5mg BD</b> <b>Reduce dose to 2.5mg BD</b> if CrCl is 15-29mls/min OR if 2 or more of the following >80 years old or a body weight of 60kg or less or renal impairment (Serum Creatinine > 133 micromol/L) <b>Do not use if CrCl is below 15ml/min</b>	<b>Initial dose 10mg BD for 1 week</b> <b>THEN</b> <b>Standard dose 5mg BD reduced to 2.5mg BD after 6 months (if treatment to continue)</b> Use with caution of CrCL is 15-29mls/min  <b>Do not use if CrCl is below 15ml/min</b>	<i>3<sup>rd</sup> line treatment in patients unsuitable for treatment with dabigatran / dalteparin</i>  <i>See www.medicines.org.uk for dose details</i>
<b>Dabigatran</b>	<b>Standard dose 150mg BD</b> <b>Reduce dose to 110mg BD</b> if patients >80 years, patients taking interacting drugs (see SPC) Consider 110 mg bd when there is a low risk of thromboembolism and the bleeding risk is high (see SPC)  <b>Do not use if CrCl is below 30ml/min</b>	<b>Following treatment with a parenteral anticoagulant for at least 5 days</b> <b>Standard dose 150mg BD</b> <b>Reduce dose to 110mg BD</b> if patients >80 years, patients taking interacting drugs (see SPC) Consider 110 mg bd when there is a low risk of thromboembolism and the bleeding risk is high (see SPC)  <b>Do not use if CrCl is below 30ml/min</b>	<b>Standard dose 220mg OD</b> <b>Reduce dose to 150mg OD</b> if patients >75 years old, CrCl is 30-50mls/min, or patient taking interacting drugs (see SPC). <b>Reduce dose to 75mg OD</b> if CrCl is 30-50mls/min AND patient taking interacting drugs <b>Do not use if CrCl is below 30ml/min</b>
<b>Rivaroxaban</b>	<b>Standard dose 20mg OD</b> <b>Reduce dose to 15mg OD</b> if CrCl is 15-49ml/min. Extra caution is required if CrCl is 15-29mls/min due to an increased bleeding risk <sup>10</sup>  <b>Do not use if CrCl is below 15ml/min</b>	<b>Initial dose 15mg BD for 3 weeks</b> <b>THEN</b> <b>Standard dose 20mg OD</b> <b>Reduce on-going dose to 15mg OD</b> if CrCL is 15-49ml/min and patient's assessed risk of bleeding outweighs risk of recurrent DVT/PE <b>Do not use if CrCl is below 15ml/min</b>	<i>3<sup>rd</sup> line treatment in patients unsuitable for treatment with dabigatran / dalteparin</i>  <i>See www.medicines.org.uk for dose details</i>
<b>Edoxaban</b>	<b>Standard Dose 60mg OD – with or without food</b> <b>Reduce dose to 30mg OD if:</b> CrCl is 15-49ml/min Body weight ≤ 60 kg Select P-gp inhibitors: ciclosporin, dronedarone, erythromycin, ketoconazole  <b>Do not use if CrCl is below 15ml/min</b>	<b>Following initial use of parenteral anticoagulant for at least 5 days:</b> <b>Standard Dose 60mg OD – with or without food</b> <b>Reduce dose to 30mg OD if:</b> CrCl is 15-49ml/min Body weight ≤ 60 kg Select P-gp inhibitors: ciclosporin, dronedarone, erythromycin, ketoconazole <b>Do not use if CrCl is below 15ml/min</b>	Not licensed

## DALTEPARIN PRESCRIBING INFORMATION FOR PRIMARY CARE

Indication	Dose of Dalteparin	Duration of Treatment														
<b>Prophylaxis of VTE</b> <a href="#">(NICE NG89)</a>	5000 units once daily (2500 units daily in dialysis patients)	Dependent on type of surgery and/or time taken for patient's mobility to return to normal state														
<b>Treatment of DVT / PE</b>  See <a href="http://www.bnf.org.uk">www.bnf.org.uk</a>	<table border="0"> <thead> <tr> <th>Patient weight</th> <th>Once daily dose</th> </tr> </thead> <tbody> <tr> <td>Under 46kg</td> <td>7500 units</td> </tr> <tr> <td>46-56 kg</td> <td>10 000 units</td> </tr> <tr> <td>57-68 kg</td> <td>12 500 units</td> </tr> <tr> <td>69-82 kg</td> <td>15 000 units</td> </tr> <tr> <td>83 kg and over</td> <td>18 000 units</td> </tr> </tbody> </table>	Patient weight	Once daily dose	Under 46kg	7500 units	46-56 kg	10 000 units	57-68 kg	12 500 units	69-82 kg	15 000 units	83 kg and over	18 000 units	For patients initiated on warfarin: until INR in range for 2 days (minimum 5 days of dalteparin) Where warfarin contraindicated: for 3 to 6 months  Longer courses or life long treatment may be justified in patients at continued high risk of VTE		
Patient weight	Once daily dose															
Under 46kg	7500 units															
46-56 kg	10 000 units															
57-68 kg	12 500 units															
69-82 kg	15 000 units															
83 kg and over	18 000 units															
<b>PREGNANCY</b> <b>Prophylaxis of VTE during Pregnancy and/or following delivery</b>  <a href="#">(RCOG Guideline 37a)</a> <b>Treatment dose</b> - during pregnancy - following delivery	<table border="0"> <thead> <tr> <th>Patient weight (use booking weight)</th> <th>Once daily dose</th> </tr> </thead> <tbody> <tr> <td>Under 50kg</td> <td>2500 units</td> </tr> <tr> <td>50-90 kg</td> <td>5000 units*</td> </tr> <tr> <td>91-130 kg</td> <td>7500 units</td> </tr> <tr> <td>131-170 kg</td> <td>10 000 units</td> </tr> <tr> <td>Over 170 kg</td> <td>75 units/kg/day</td> </tr> </tbody> </table> 100 units per kg every 12 hours 200 units per kg once daily	Patient weight (use booking weight)	Once daily dose	Under 50kg	2500 units	50-90 kg	5000 units*	91-130 kg	7500 units	131-170 kg	10 000 units	Over 170 kg	75 units/kg/day	During pregnancy and/or up to 6 weeks after delivery (dependent on level of risk).  *High prophylactic (intermediate dose) for women weighing 50-90 kg: 5000 units twice daily. Please see RCOG Guideline 37a for when this dose is indicated.  As Treatment of DVT/PE above (warfarin can be used postnatally, once risk or haemorrhage is low, usually 5 – 7 days after delivery).		
Patient weight (use booking weight)	Once daily dose															
Under 50kg	2500 units															
50-90 kg	5000 units*															
91-130 kg	7500 units															
131-170 kg	10 000 units															
Over 170 kg	75 units/kg/day															
<b>Extended treatment and prophylaxis of VTE in patients with solid tumours</b>  See <a href="http://www.bnf.org.uk">www.bnf.org.uk</a>	<table border="0"> <thead> <tr> <th>Patient weight</th> <th>Once daily dose</th> </tr> </thead> <tbody> <tr> <td>Under 46 kg</td> <td>7500 units for 6 months</td> </tr> <tr> <td>46 – 56 kg</td> <td>10 000 units for 30 then 7500 units for 5 months</td> </tr> <tr> <td>57 – 68 kg</td> <td>12 500 units for 30 days then 10 000 units for 5 months</td> </tr> <tr> <td>69 – 82 kg</td> <td>15 000 units for 30 days then 12 500 units for 5 months</td> </tr> <tr> <td>83 kg – 98 kg</td> <td>18 000 units for 30 days then 15 000 units for 5 months</td> </tr> <tr> <td>99 kg and over</td> <td>18 000 units for 6 months</td> </tr> </tbody> </table> Relevance of continuing treatment beyond this period will be evaluated according to individual risk/benefit ratio, taking into account particularly the progression of cancer. Doses may be interrupted or reduced in chemotherapy induced thrombocytopenia – as advised by haematologist / oncologist	Patient weight	Once daily dose	Under 46 kg	7500 units for 6 months	46 – 56 kg	10 000 units for 30 then 7500 units for 5 months	57 – 68 kg	12 500 units for 30 days then 10 000 units for 5 months	69 – 82 kg	15 000 units for 30 days then 12 500 units for 5 months	83 kg – 98 kg	18 000 units for 30 days then 15 000 units for 5 months	99 kg and over	18 000 units for 6 months	
Patient weight	Once daily dose															
Under 46 kg	7500 units for 6 months															
46 – 56 kg	10 000 units for 30 then 7500 units for 5 months															
57 – 68 kg	12 500 units for 30 days then 10 000 units for 5 months															
69 – 82 kg	15 000 units for 30 days then 12 500 units for 5 months															
83 kg – 98 kg	18 000 units for 30 days then 15 000 units for 5 months															
99 kg and over	18 000 units for 6 months															
<b>Further notes</b>	For patients with an increased risk of bleeding, an equivalent twice daily dosing may be recommended.  Monitor FBC, BCP and coagulation (PT and APTT) at baseline to check for contraindications to anticoagulation and that renal function is adequate. Monitoring with anti-Xa assay may be appropriate in pregnancy & renal failure – obtain specialist advice.															

Renal failure : Dalteparin can accumulate in patients with GFR < 30 ml/min. If dalteparin treatment dose is prescribed, dose should be reduced and patient monitored closely for bleeding. Guidelines on the diagnosis and management of heparin-induced thrombocytopenia <a href="http://onlinelibrary.wiley.com/doi/10.1111/bjh.12059/full">http://onlinelibrary.wiley.com/doi/10.1111/bjh.12059/full</a>
--

**CrCl vs eGFR:** whilst SPCs state dose adjustments in relation to a patient's CrCl, eGFR is used in practice. eGFR is normalised to a standard body surface area of 1.73 m<sup>2</sup> so is less reliable at extremes of body weight. **For prescribing of DOACs it is recommended to adjust dose according to calculated creatinine clearance<sup>4</sup>.**

In certain patient groups eg people of African-Caribbean / African family origin, people with extremes of muscle mass e.g. bodybuilders, amputees or those with muscle wasting disorders, interpret eGFR with caution. Reduced muscle mass will lead to overestimation of actual GFR and increased muscle mass to underestimation of actual GFR. For more information see BNF "Principles of dose adjustment in renal impairment" <https://www.evidence.nhs.uk/formulary/bnf/current/guidance-on-prescribing/prescribing-in-renal-impairment/principles-of-dose-adjustment-in-renal-impairment>

### References

1. Summary of Product. Electronic Medicines Compendium. <http://emc.medicines.org.uk/>
2. National Institute for Health and Care Excellence (NICE). CG 144. Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing. London: National Clinical Guideline Centre. JUNE 2014. [Accessed on: 01 DEC 2014]. Available from: <http://www.nice.org.uk>
3. Heidbuchel H, Verhamme P, Alings M et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. *Europace* (2013) 15; 625-651. <http://europace.oxfordjournals.org/content/europace/15/5/625.full.pdf>
4. MHRA Drug Safety Update October 2019. Prescribing medicines in renal impairment: using the appropriate estimate of renal function to avoid the risk of adverse drug reactions. <https://www.gov.uk/drug-safety-update/prescribing-medicines-in-renal-impairment-using-the-appropriate-estimate-of-renal-function-to-avoid-the-risk-of-adverse-drug-reactions> accessed 24/3/20

### Guidance on switching between anticoagulants

See table below

# ***HERPC***

***Hull & East Riding Prescribing Committee***

To	Warfarin	From Parenteral or SC (UFH or LMWH or Fondaparinux)	Apixaban	Dabigatran	Edoxaban	Rivaroxaban
From Warfarin See links below	<p>For further advice on converting between anticoagulants contact Medicines Information (HRI 4411)</p> <p><b>*In patients with renal impairment, higher than therapeutic plasma concentrations are expected and a longer interval may be required.</b></p>	<p><b>Treatment of DVT/PE;</b> stop warfarin and initiate treatment dose LMWH when INR &lt;2.0.</p> <p><b>Prevention of stroke and systemic embolism;</b> review thrombotic risk on a case-by-case basis and consider initiating prophylactic or treatment dose LMWH once INR &lt;2.0.</p>	Discontinue warfarin and commence apixaban as soon as INR is <2.0.	Discontinue warfarin and commence dabigatran as soon as INR is <2.0.	Discontinue warfarin and commence edoxaban as soon as INR is <2.5.	<p><b>DVT, PE and prevention of recurrence;</b> stop warfarin and initiate rivaroxaban once INR is ≤2.5.</p> <p><b>Prevention of stroke and systemic embolism;</b> stop warfarin and initiate rivaroxaban once INR ≤3.0.</p>
From Parenteral (UFH) or SC (LMWH or Fondaparinux)	Commence warfarin in combination with LMWH, and monitor INR. Discontinue LMWH once INR in therapeutic range for 2 consecutive days.	<p>Stop UFH. Start LMWH or Fondaparinux within 1 hour.</p> <p>Stop LMWH or Fondaparinux. Start UFH at next scheduled LMWH dose.</p>	Discontinue LMWH or Fondaparinux and commence apixaban at the time of the next scheduled dose. These medicinal products should not be administered simultaneously.	Discontinue LMWH or Fondaparinux and commence dabigatran 0-2 hours before the time that the next scheduled dose of LMWH would be due. For UFH, start dabigatran at time of stopping UFH.	Discontinue LMWH or Fondaparinux and commence edoxaban at the time of the next scheduled dose. For UFH: discontinue the infusion and start edoxaban 4 hours later.	Discontinue LMWH and commence rivaroxaban 0-2 hours before the time that the next scheduled dose of LMWH would be due. For UFH, start rivaroxaban at time of stopping UFH.
Apixaban	Commence warfarin in combination with apixaban. Apixaban should be discontinued when INR is ≥ 2.0. Measure INR prior to each dose of apixaban. <b>MONITOR INR DAILY</b>	Discontinue apixaban and commence LMWH at the time that the next scheduled dose of apixaban would be due.		Discontinue apixaban and commence dabigatran at the time that the next scheduled dose of apixaban would be due*.	Discontinue apixaban and commence edoxaban at the time that the next scheduled dose of apixaban would be due*.	Discontinue apixaban and commence rivaroxaban at the time that the next scheduled dose of apixaban would be due*.
Dabigatran	<p><b>Conversion protocol depends on renal function.</b></p> <p>For CrCl ≥ 50ml/minute, commence warfarin 3 days prior to discontinuing dabigatran.</p> <p>For CrCl 30-50ml/minute, commence warfarin 2 days prior to discontinuing dabigatran.</p> <p><u>NB: dabigatran can increase INR. INR measurements should be interpreted cautiously until dabigatran has been stopped for 2 days.</u></p>	Discontinue dabigatran and commence LMWH 12-hours after the last dose of dabigatran was administered (for orthopaedic prophylaxis: wait 24 hours from last dabigatran dose).	Discontinue dabigatran and commence apixaban at the time that the next scheduled dose of dabigatran would be due*.		Discontinue dabigatran and commence edoxaban at the time that the next scheduled dose of dabigatran would be due*.	Discontinue dabigatran and commence rivaroxaban at the time that the next scheduled dose of dabigatran would be due*.
Edoxaban	<p><b>Oral option:</b> For patients taking 60 mg of edoxaban, reduce the dose to 30 mg and begin warfarin concomitantly. For patients receiving 30 mg of edoxaban, reduce the edoxaban dose to 15 mg and begin warfarin concomitantly. INR must be measured at least weekly and just prior to the daily dose of edoxaban to minimize the influence of edoxaban on INR measurements. Once a stable INR ≥2.0 is achieved, edoxaban should be discontinued and the warfarin continued. <b>Parenteral option:</b> Discontinue edoxaban and administer a parenteral anticoagulant and warfarin at the time of the next scheduled edoxaban dose. Once a stable INR ≥2.0 is achieved, the parenteral anticoagulant should be discontinued and the warfarin continued.</p>	Discontinue edoxaban and start the parenteral anticoagulant at the time the next dose of edoxaban was due.	Wait 24 hours after last dose of edoxaban to initiate apixaban.	Wait 24 hours after last dose of edoxaban to initiate dabigatran.		Wait 24 hours after last dose of edoxaban to initiate rivaroxaban.
Rivaroxaban	Commence warfarin in combination with rivaroxaban. Rivaroxaban should be discontinued when INR is in therapeutic range. Measure INR prior to each dose of rivaroxaban being administered. <b>MONITOR INR DAILY</b>	Discontinue rivaroxaban and commence LMWH at the time that the next scheduled dose of rivaroxaban would be due.	Discontinue rivaroxaban and commence apixaban at the time that the next scheduled dose of rivaroxaban would be due*.	Discontinue rivaroxaban and commence dabigatran at the time that the next scheduled dose of rivaroxaban would be due*.	Discontinue rivaroxaban and commence edoxaban at the time that the next scheduled dose of rivaroxaban would be due*.	